VAN WIJMEERSCH, Bart

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Refined By:
Author:  Izquierdo, G.
Date Issued:  2018

Results 1-6 of 6 (Search time: 0.002 seconds).

Issue DateTitleContributor(s)TypeCat.
12018Determinants of MS re-activation after discontinuing therapiesHusin, H.; Wallace, J.; Malpas, C.; Sharmin, S; Horakova, D.; Havrdova, E. Kubala; Izquierdo, G.; Eichau, S.; Prat, A.; Girard, M.; Duquette, P.; Trojano, M.; Grammond, P.; Lugaresi, A.; Onofrj, M.; Ozakbas, S.; Butzkueven, H.; Sola, P.; Ferraro, D.; Alroughani, R.; Grand'Maison, F.; Terzi, M.; Lechner-Scott, J.; Boz, C.; Hupperts, R.; Shaygannejad, V.; Bergamaschi, R.; Pucci, E.; Van Pesch, V.; Hodgkinson, S.; McCombe, P.; Granella, F.; Slee, M.; VAN WIJMEERSCH, Bart; Karabudak, R.; Prevost, J.; Petersen, T.; Spitaleri, D.; Barnett, M.; Solaro, C.; Iuliano, G.; Verheul, F.; Ramo-Tello, C.; Turkoglu, R.; Fernandez Bolanos, R.; Butler, E.; Macdonell, R.; Soysal, A.; Betancur, M. Moreno; Kalincik, T.Journal ContributionM
22018Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extensionVAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia; Wiendl, H.Journal ContributionM
32018Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extensionWiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, BartJournal ContributionM
42018Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I)Broadley, S.; Wiendl, Heinz; Fernandez, O.; Freedman, M. S.; Izquierdo, G.; Lycke, J.; Pozzilli, C.; Sharrack, B.; Singer, B. A.; Steingo, B.; Vermersch, P.; Wray, S.; VAN WIJMEERSCH, Bart; Ziemssen, T.; Margolin, D. H.; Thangavelu, K.; Boster, A.Journal ContributionM
52018No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosisWiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, BartJournal ContributionM
62018No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosisWiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, BartJournal ContributionM